Treatment Outcomes and Prognostic Factors in Mexican Patients with Endometrial Carcinoma with Emphasis on Patients Receiving Radiotherapy after Surgery: An Institutional Perspective
Table 4
Treatment characteristics of Mexican patients with endometrial carcinoma.
Characteristic
Patients
Percentage
Surgery
TAH-BSO
120
29.1
TAH-BSO-pelvic LND
20
4.9
TAH-BSO-Pelvic/para aortic LND and omentum biopsy
271
65.8
Pelvic exenteration
1
.2
Lymph node dissection
Pelvic
296/412
71.8
Para aortic
273/412
66.3
Chemotherapy
Yes
59
14.3
No
353
85.7
Concurrent with RT
25/59
6.1
Sequential chemotherapy
31/59
7.5
Adjuvant without RT
3/59
.7
Chemotherapy agents used
Cisplatin/adriamicin
15
3.6
Cisplatin
2
.5
CisCA regimen
4
1.0
Carboplatin/adriamicin/ciclophosphamide
1
.2
PVC regimen
3
.7
Adriamicin
3
.7
Cisplatin/adriamicin/ciclophosphamide
1
.2
Ciclophosphamide/adriamicin
1
.2
Cisplatin/paclitaxel
2
.5
Carboplatin
22
5.3
Carboplatin/paclitaxel
4
1.0
Gemcitabine
1
.2
Hormone therapy
Yes
10
2.4
No
402
97.6
Radiotherapy
Yes
270
65.53
No
142
34.47
Pelvic EBRT
11/270
4.08
WART + pelvic RT + VBT
8/270
2.96
EBRT + VBT
241/270
89.26
VBT
7/270
2.59
Pelvic + retroperitoneum EBRT + VBT
3/270
1.11
Brachytherapy
Yes
255/412
61.89
No
157/412
38.11
High-dose rate
14/255
5.49
Low-dose rate
241/255
94.51
TAH-BSO: total abdominal hysterectomy, TAH-BSO-LND: total abdominal histerectomy and lymph node dissection, EBRT: external beam radiotherapy, WART: whole abdominal radiotherapy, and VBT: vaginal vault brachytherapy.
